Supernus Pharmaceuticals, Inc.
SUPN
$55.39
-$1.11-1.97%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 522.60M | 463.59M | 453.61M | 403.21M | 347.19M |
| Total Receivables | 140.83M | 145.64M | 142.08M | 145.41M | 152.49M |
| Inventory | 44.02M | 49.42M | 54.29M | 63.98M | 68.16M |
| Prepaid Expenses | 31.42M | 28.93M | 36.09M | 27.40M | 23.17M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | 738.87M | 687.58M | 686.07M | 640.00M | 591.00M |
|
|
|||||
| Total Current Assets | 738.87M | 687.58M | 686.07M | 640.00M | 591.00M |
| Net Property, Plant & Equipment | 32.95M | 34.06M | 36.02M | 37.96M | 40.04M |
| Long-term Investments | 117.02M | 117.02M | 117.02M | 117.02M | 117.02M |
| Goodwill | 117.02M | 117.02M | 117.02M | 117.02M | 117.02M |
| Total Other Intangibles | 481.31M | 502.13M | 521.91M | 540.16M | 559.64M |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 12.26M | 6.50M | 7.05M | 7.56M | 8.12M |
| Total Assets | 1.38B | 1.35B | 1.37B | 1.34B | 1.32B |
|
|
|||||
| Total Accounts Payable | 8.22M | 7.07M | 4.59M | 6.39M | 4.63M |
| Total Accrued Expenses | 197.03M | 184.09M | 180.21M | 171.88M | 184.88M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 7.39M | 5.94M | 6.89M | 9.23M | 9.68M |
| Total Finance Division Other Current Liabilities | 73.73M | 84.67M | 100.72M | 104.01M | 109.46M |
| Total Other Current Liabilities | 73.73M | 84.67M | 100.72M | 104.01M | 109.46M |
| Total Current Liabilities | 286.36M | 281.77M | 292.40M | 291.51M | 308.66M |
|
|
|||||
| Total Current Liabilities | 286.36M | 281.77M | 292.40M | 291.51M | 308.66M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 24.38M | 26.37M | 27.38M | 28.93M | 30.29M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 7.76M | 8.45M | 12.56M | 15.12M | 19.43M |
| Total Liabilities | 318.51M | 316.59M | 332.34M | 335.55M | 358.38M |
|
|
|||||
| Common Stock & APIC | 497.00M | 486.27M | 479.50M | 465.97M | 455.23M |
| Retained Earnings | 567.10M | 544.60M | 556.43M | 541.10M | 502.60M |
| Treasury Stock & Other | -200.00K | -159.00K | -189.00K | 78.00K | -372.00K |
| Total Common Equity | 1.06B | 1.03B | 1.04B | 1.01B | 957.45M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 1.06B | 1.03B | 1.04B | 1.01B | 957.45M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 1.06B | 1.03B | 1.04B | 1.01B | 957.45M |
|
|
|||||